• HOME
  • Therapeutics
  • Technology
  • Team
  • News
  • About
  • HOME
  • Therapeutics
  • Technology
  • Team
  • News
  • About
  • V1fz3suL-

    Antimicrobial resistance is an
    increasingly serious threat to global public health

  • N1WT6iuIb

    If antibiotics lose their eFFEctiveness, key medical
    procedures could become too dangerous to perform.

  • N1PV2juIW

    An estimated 700.000 lives are lost yearly to
    anti-microbial resistant infections.
    The estimate for year 2050 is 10 million lives yearly.

  • HOME
  • News
  • STEFAN JÖKULL SVEINSSON JOINS AKTHELIA’S BOARD

STEFAN JÖKULL SVEINSSON JOINS AKTHELIA’S BOARD

June 22, 2016

Akthelia is very proud to announce that Dr. Stefán Jökull Sveinsson has joined Akthelia’s board of directors. Dr. Sveinsson was Executive Vice President-Research & Development at Actavis for over 15 years where he directed drug development. Prior to that, he directed drug development at Delta and was a professor in Pharmacology at the University of Iceland. After leaving Actavis he has worked as an independent advisor in the pharmaceutical industry.

Eldri fréttir

  • Antimicrobial Peptides 2019, Gordon Research Conference
    January 28, 2019
  • New substances are treating infections by activating the immune system
    January 15, 2019
  • AKTHELIA SELECTED AS FINALIST FOR THE SCIENCE 2 STARTUP EVENT
    February 27, 2018
  • NEW ARTICLE ON TREATING CHOLERA WITH ONE OF THE APD'S
    June 15, 2017
  • MORGUNBLAÐIÐ, 20/10 2017
    November 15, 2017
  • A CLINICAL TRIAL SHOWS THAT ONE OF AKTHELIA’S ACTIVES SPEEDS RECOVERY OF TUBERCULOSIS.
    June 22, 2016
  • AKTHELIA APPLIES FOR PATENT FOR A NEW CLASS OF CHEMICALS
    June 1, 2016
  • JÓN INGI BENEDIKTSSON JOINS AKTHELIA AS GENERAL MANAGER
    June 22, 2016
  • MEMBERS OF AKTHELIA MANAGEMENT PLAY MAJOR ROLES AT ANTIBACTERIAL CONFERENCE.
    October 10, 2009

AKTHELIA

  • Grandagarði 16, 101 Reykjavik
  • akthelia@akthelia,is
  • 610502-6440
  • Twitter
© 2021 AKTHELIA